Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Journal of Experimental and Clinical Pharmacy (JECP)
Andyra, Vania Uly
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Dentistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
In Silico Exploration of Suruhan Leaves (Peperomia pellucida) for Triple-Negative Breast Cancer Therapy Targeting AURKA Rovik, Anwar; Andyra, Vania Uly; Afifah, Laelatul
Journal of Experimental and Clinical Pharmacy (JECP) Vol 4, No 2 (2024): August 2024
Publisher : Poltekkes Kemenkes Gorontalo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52365/jecp.v4i2.1119

Abstract

Breast cancer is the most common type of cancer worldwide. One of the most widely used chemotherapeutic agents in the treatment of breast cancer is doxorubicin. However, doxorubicin has been reported to cause side effects. Suruhan (Peperomia pellucida) contains bioactive compounds that might protect against breast cancer cells. This study aims to analyze the bioactive compound activity of Suruhan leaves in triple-negative breast cancer in silico. The study was conducted by reviewing published literature on bioactive compounds in Suruhan leaves, predicting the protein target, analyzing the gene expression in triple-negative breast cancer (TNBC) patients, analyzing the protein interactions, and examining patient survival. There are five common bioactive compounds in Suruhan leaves, including peperomin A; 6,8-dihydroxy kaempferol 3,6,7,4'-tetramethyl ether 8-neohesperidoside; dillapiole; carotol; and pellucidin A. AURKA is a target protein for bioactive compounds that are also overexpressed in TNBC patients. AURKA has strong interactions with many proteins, including TPX2, NEDD9, CCNB2, CDC20, PLK1, BIRC5, INCENP, TACC3, TP53, and MYCN. The AURKA has emerged as a promising target for TNBC therapy.
Design and Stability Evaluation of Active Peptides from Indonesian Echinozoa as Acetylcholinesterase (AChE) Inhibitors for Alzheimer’s Therapy Afifah, Laelatul; Andyra, Vania Uly; Laksitorini, Marlyn Dian; Nuringtyas, Tri Rini
The Indonesian Biomedical Journal Vol 17, No 5 (2025)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v17i5.3837

Abstract

BACKGROUND: Alzheimer’s disease is characterized by cognitive decline resulting from decreased acetylcholine (ACh) levels due to excessive acetylcholinesterase (AChE) activity. Current therapies, such as galantamine, have several side effects. Bioactive peptides derived from marine Echinozoa (sea urchins and sea cucumbers) have emerged as promising therapeutic agents owing to their structural diversity and diverse bioactivities. Previous studies identified peptides from sea cucumbers and sea urchins collected along the southern coast of Gunung Kidul, Yogyakarta (VLCAGDLR, SWIGLK, MNGKKITVRPR, and KTKDLK), which exhibit acetylcholinesterase (AChE) inhibitory activity. However, the therapeutic use of these peptides is challenged by blood–brain barrier (BBB) penetration and stability issues. Therefore, this study was conducted to identify candidate peptides through in silico analysis and to evaluate their stability in phosphate-buffered saline (PBS) as potential AChE inhibitors.METHODS: Molecular docking was conducted to evaluate peptide binding affinity to the active site. The best candidate peptides were synthesized and tested in vitro for AChE inhibition using a colorimetric method. Stability was assessed in PBS by monitoring aggregation through turbidity and Congo Red assays.RESULTS: The sea cucumber peptide SWIGLK showed strong binding affinity (–10.2 kcal/mol) and 12.11% inhibition at 0.19 mM, while the sea urchin peptide KTKDLK exhibited –8.2 kcal/mol and 11.50% inhibition at 0.19 mM. Both peptides remained stable in PBS without aggregation for up to 48 h.CONCLUSION: SWIGLK and KTKDLK demonstrate the most significant AChE inhibitory activity and maintained structural stability, hence supporting their potential as peptide-based candidates for Alzheimer’s therapy.KEYWORDS: Alzheimer, AChE inhibitor, holothuroidea, echinoidea, bioactive peptide, peptide stability
Co-Authors Afifah, Laelatul Marlyn Dian Laksitorini, Marlyn Dian Rovik, Anwar Tri Rini Nuringtyas